GlycoGenesys, Inc. GCS-100 Cancer Drug Candidate Subject of Abstract in The American Society of Hematology's Annual Meeting Abstracts Book.

BOSTON -- GCS-100's Target, Galectin-3, Widely Expressed in Multiple Myeloma

Multiple Myeloma Clinical Trial Enrolling at Several Sites in US

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company focused on drug development, today announced that its cancer drug candidate, GCS-100, was the subject of an abstract published in Blood, the official journal of The American Society of Hematology, in connection with the Society's 47th Annual Meeting.

The abstract entitled "Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone", was authored by researchers at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA and GlycoGenesys, Boston MA.

As background, Galectin-3 (Gal-3) is a carbohydrate-binding protein that is one of the targets of GCS-100, a complex carbohydrate drug candidate that is currently in clinical development for treatment of multiple myeloma, solid tumors and a clinical trial for chronic lymphocytic leukemia is planned to initiate before year-end. Gal-3 is an important protein involved in multiple cellular processes including growth, differentiation, adhesion and programmed cell death (apoptosis). It is known to play a role in the transformation and metastasis of tumor cells. Previous studies have shown that Gal-3 expression inhibits the mitochondrial release of cytochrome-c, a key protein involved in the induction of apoptosis, or programmed cell death.

The abstract shows that Gal-3 is widely and differentially expressed in a variety of multiple myeloma cell lines and patients' cells. The authors' reported that GCS-100 binds to Gal-3 and can trigger apoptosis in multiple myeloma cells as well as enhance the anti-tumor activity of the conventional agent, dexamethasone. Additionally, sub-toxic concentrations of GCS-100 and dexamethasone were shown to markedly decrease the expression of Gal-3 in multiple myeloma cells and lead to the release of cytochrome-c. This new data suggests that GCS-100 and dexamethasone can overcome the inhibitory effect of Gal-3 on cytochrome-c to cause programmed cell death. In conclusion, the authors propose that inhibition of Gal-3 may augment the anti-tumor activity of therapeutic regimens.

In previously published papers, GCS-100 has been shown to induce selective programmed cell death in multiple myeloma patient cells, including those refractory to traditional chemotherapies such as dexamethasone, Velcade(R), and Thalomid(R).

Bradley J. Carver, CEO and President of GlycoGenesys, Inc., stated, "Recent publications including this ASH abstract continue to support the design of our current Phase I/II clinical trial, which is evaluating GCS-100, alone and in combination with dexamethasone, to treat patients with multiple myeloma. Since Galectin-3 is widely expressed in multiple myeloma cells, its inhibition by GCS- 100 may increase the anti-tumor activity of existing therapies. We look forward to reporting on our clinical trial results next year."

Abstract #4447 appears in Blood, Volume 106, issue 11, November 16, 2005

Keywords: Glycoprotein|BCL2|Experimental therapeutics

Wednesday, November 30, 2005

http://www.abstracts2view.com/hem_ash05atlanta/view.php?nu= HEM05L1_3831

(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

About GlycoGenesys, Inc.

GlycoGenesys, Inc. is a biotechnology company focused on carbohydrate drug development. The Company's drug candidate GCS-100, a unique compound to treat cancer, has been evaluated in previous clinical trials at low dose levels in patients with colorectal, pancreatic and other solid tumors with stable disease and partial response documented. The Company currently is completing a Phase I dose escalation trial to evaluate higher dose levels of GCS-100LE, a low ethanol formulation of GCS-100, at Sharp Memorial Hospital, Clinical Oncology Research in San Diego, California and the Arizona Cancer Center in both Tucson and Scottsdale, Arizona. In addition, GCS-100LE is being evaluated in a Phase I/II trial for multiple myeloma at the Dana-Farber Cancer Institute in Boston, Massachusetts, Roswell Park Cancer Institute in Buffalo, New York and Emory's Winship Cancer Institute. Further clinical trials are planned 2006. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.

Safe Harbor Statement

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, risks of product development (such as failure to demonstrate efficacy or safety), risk related to FDA and other regulatory procedures, market acceptance risks, the impact of competitive products and pricing, the results of current and future licensing, joint ventures and other collaborative relationships, risks relating to raising sufficient capital to fund the Company's operations, developments regarding intellectual property rights and litigation, and other risks identified in the Company's Securities and Exchange Commission filings. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.